---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-008304"
form_type: "8-K"
ticker: "GLUE"
cik: "0001826457"
company_name: "Monte Rosa Therapeutics, Inc."
filed_at: "2023-03-16T23:59:59+00:00"
generated_at: "2026-06-18T00:55:43.130390+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Monte Rosa reports FY 2022 net loss of $108.5M; MRT-2359 Phase 1/2 data expected H2 2023

## Summary
- FY 2022 net loss $108.5M (vs $74.0M in 2021); cash & securities $268.1M, runway into 2025.
- MRT-2359 Phase 1/2 ongoing; initial Phase 1 PK/PD/safety data expected H2 2023.
- FDA granted Fast Track for MRT-2359 in pretreated metastatic NSCLC with L-MYC/N-MYC expression.
- VAV1 degrader advanced to lead optimization; multiple development candidates expected in 2023.
- Promoted Jennifer Champoux to Chief People & Operations Officer; appointed Magnus Walter SVP Chemical Sciences.

## SEC filing metadata
- accession: 0000950170-23-008304
- form_type: 8-K
- ticker: GLUE
- cik: 0001826457
- company_name: Monte Rosa Therapeutics, Inc.
- filed_at: 2023-03-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826457/000095017023008304/0000950170-23-008304-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826457/000095017023008304/glue-20221110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-008304
- JSON: https://secwatch.observer/filing/0000950170-23-008304.json
- Plain text: https://secwatch.observer/filing/0000950170-23-008304.txt

## Key facts
- Earnings Releases
  Monte Rosa Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2022.
  - Period: the fourth quarter and full year ended December 31, 2022
  - Result: reported results
  source text: On March 16, 2023, Monte Rosa Therapeutics, Inc. (the "Company") announced its financial results for the quarter and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1826457/000095017023008304/0000950170-23-008304-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.